Jenny Seligmann, Professor of Gastrointestinal and Translational Oncology and Honorary Consultant in Medical Oncology at the University of Leeds, shared an article on X:
“Now online – my 2 fav topics in one paper.
- FOxTROT Ph2 FOLFOX+/- pani in locally advanced RAS/RAF-wt colon cancer.
- Convincing activity of anti-EGFR on long term outcomes, esp in hyperselected patients.
Time to re-think targeted agents in LACC/LARC.”
Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT Trial embedded phase II population.
Authors: J.F. Seligmann, et al.
